Table 6.14.

Examples of therapeutic cancer vaccines in clinical trials

Cancer type	Vaccine approach	Manufacturer/Developer
Bladder cancer	Multi-epitope cancer vaccine to the MUC1 tumour-associated antigen	Vaxil Bio Therapeutics Ltd
Brain tumours	Dendritic cell vaccine	Samuel Oschin Comprehensive Cancer Institute
Cervical cancer	RO5217790 consists of recombinant modified vaccinia Ankara viral vector encoding mutated forms of human papillomavirus type 16 genes for the viral oncoproteins E6 and E7 and the hIL2	Roche
Melanoma	DNA vaccine (tyrosinase-related protein 2) – an immunobody adjuvant approach ASCI, MAGE-A3/AS15 Human anti-CTLA-4 antibody (MDX-010) in combination with a gp100 melanoma vaccine (MDX-1379)	Scancell Ltd GSK Biologicals Bristol-Myers Squibb
Lung cancer	Modified mRNA vaccine encoding five antigens including NY-ESO-1 ASCI, MAGE-A3/AS15	CureVac GmbH GSK Biologicals
Colorectal cancer	Modified vaccinia Ankara encoding the tumour antigen 5T4	Oxford BioMedica

MUC1, Mucin 1 cell surface; hIL2, human cytokine interleukin-2; ASCI, antigen-specific cancer immunotherapeutics; MAGE, melanoma-associated antigen; CTL, cytotoxic T lymphocyte. Every effort has been made to verify the information in this table. The information included is not meant to be exhaustive but is intended to provide an overview of the subject matter.